Signaturefd LLC Raises Stock Holdings in Enovis Co. (NYSE:ENOV)

Signaturefd LLC increased its holdings in shares of Enovis Co. (NYSE:ENOV) by 197.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,257 shares of the company’s stock after acquiring an additional 1,498 shares during the quarter. Signaturefd LLC’s holdings in Enovis were worth $126,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ENOV. UMB Bank n.a. purchased a new position in Enovis in the third quarter valued at about $31,000. Bernzott Capital Advisors lifted its stake in Enovis by 14.3% in the third quarter. Bernzott Capital Advisors now owns 72,905 shares of the company’s stock valued at $3,844,000 after purchasing an additional 9,145 shares during the last quarter. Defender Capital LLC. grew its holdings in Enovis by 66.7% during the third quarter. Defender Capital LLC. now owns 10,000 shares of the company’s stock valued at $527,000 after purchasing an additional 4,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Enovis by 13.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,986 shares of the company’s stock worth $474,000 after buying an additional 1,037 shares during the last quarter. Finally, Strs Ohio lifted its position in shares of Enovis by 16.5% during the 3rd quarter. Strs Ohio now owns 16,558 shares of the company’s stock valued at $873,000 after buying an additional 2,342 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Up 1.1 %

Shares of ENOV opened at $55.89 on Tuesday. The firm has a market cap of $3.07 billion, a P/E ratio of -91.62 and a beta of 1.97. Enovis Co. has a 1 year low of $43.04 and a 1 year high of $66.14. The stock has a 50 day simple moving average of $59.80 and a two-hundred day simple moving average of $55.65. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.76 by $0.03. The company had revenue of $455.00 million for the quarter, compared to analyst estimates of $444.34 million. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The firm’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.72 EPS. On average, analysts forecast that Enovis Co. will post 2.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on ENOV. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price objective on shares of Enovis in a report on Wednesday, April 10th. Canaccord Genuity Group upped their price target on shares of Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Stephens started coverage on shares of Enovis in a report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price objective for the company. UBS Group initiated coverage on Enovis in a research note on Monday, January 22nd. They set a “buy” rating and a $75.00 price objective on the stock. Finally, Wells Fargo & Company raised their target price on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $75.43.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.